Aura Debt To Assets from 2010 to 2024

AURA Stock  USD 8.95  0.08  0.89%   
Aura Biosciences' Debt To Assets are increasing over the years with slightly volatile fluctuation. Overall, Debt To Assets are expected to go to 0.01 this year. From 2010 to 2024 Aura Biosciences Debt To Assets quarterly data regression line had arithmetic mean of  0 and r-squared of  0.51. View All Fundamentals
 
Debt To Assets  
First Reported
2010-12-31
Previous Quarter
0.01053416
Current Value
0.0111
Quarterly Volatility
0.00428819
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Aura Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aura Biosciences' main balance sheet or income statement drivers, such as Net Interest Income of 7.4 M, Depreciation And Amortization of 1 M or Interest Expense of 1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.63. Aura financial statements analysis is a perfect complement when working with Aura Biosciences Valuation or Volatility modules.
  
Check out the analysis of Aura Biosciences Correlation against competitors.
For information on how to trade Aura Stock refer to our How to Trade Aura Stock guide.

Latest Aura Biosciences' Debt To Assets Growth Pattern

Below is the plot of the Debt To Assets of Aura Biosciences over the last few years. It is Aura Biosciences' Debt To Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aura Biosciences' overall financial position and show how it may be relating to other accounts over time.
Debt To Assets10 Years Trend
Slightly volatile
   Debt To Assets   
       Timeline  

Aura Debt To Assets Regression Statistics

Arithmetic Mean0
Geometric Mean0
Coefficient Of Variation122.26
Mean Deviation0
Median0
Standard Deviation0
Sample Variance0.000018
Range0.0126
R-Value0.71
Mean Square Error0.00000974
R-Squared0.51
Significance0
Slope0.0007
Total Sum of Squares0.0003

Aura Debt To Assets History

2024 0.0111
2023 0.0105
2022 0.0132
2021 0.003843
2020 6.79E-4

About Aura Biosciences Financial Statements

Aura Biosciences stakeholders use historical fundamental indicators, such as Aura Biosciences' Debt To Assets, to determine how well the company is positioned to perform in the future. Although Aura Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Aura Biosciences' assets and liabilities are reflected in the revenues and expenses on Aura Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Aura Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt To Assets 0.01  0.01 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Aura Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aura Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aura Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aura Biosciences Stock:
Check out the analysis of Aura Biosciences Correlation against competitors.
For information on how to trade Aura Stock refer to our How to Trade Aura Stock guide.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aura Biosciences. If investors know Aura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aura Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.73)
Return On Assets
(0.30)
Return On Equity
(0.51)
The market value of Aura Biosciences is measured differently than its book value, which is the value of Aura that is recorded on the company's balance sheet. Investors also form their own opinion of Aura Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aura Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aura Biosciences' market value can be influenced by many factors that don't directly affect Aura Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aura Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aura Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aura Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.